



Date: 14.08.2026

To,
BSE Limited
Listing Department
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai - 400 001

To,
National Stock Exchange of India Limited
Listing Department "Exchange Plaza,"
C-1, Block G, Bandra - Kurla Complex,
Bandra (E), Mumbai - 400 051

Scrip Code: 544666

Sub.: Outcome of the Board Meeting held on August 14, 2026 ("Meeting")

Dear Sir

Pursuant to Regulation 30 and other applicable Regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Board of Directors of the Company at their meeting held on today i.e. Friday, 14th August, 2026 inter alia, consider and approved the following matters:

1. The Un-audited Financial Results (Standalone and Consolidated): In this connection, we are enclosing herewith the following:
 - Copy of the Un-audited Financial Results (Standalone and Consolidated) of the Company for the First Quarter ended on June 30, 2026 as reviewed and recommended by the Audit Committee.
 - Copy of the Limited Review Period of the Statutory Auditors of the Company, M/s. Y M Shah & Co., Vadodara, on the above Un-audited Financial Results, (Standalone and Consolidated).
2. Approval of Board's Report and Annexures thereto: Considered and approved the Board's Report of the Company and annexures thereto under Section 134(3) of the Companies Act, 2013 read with the rules framed thereunder, for the financial year ended March 31, 2026.
3. Annual General Meeting: Convening of the 7th Annual General Meeting of the Company on Monday, September 28, 2026 at the registered office of the Company. The Notice of AGM shall be intimated separately.
4. Appointment of Scrutinizer: Considered and approved the appointment of M/s SPANJ & Associates, Practicing Company Secretary (Peer Reviewed Firm) as Scrutinizer for the 7th Annual General Meeting of the Company.

Gujarat Kidney And Superspeciality Limited

Formerly known as Gujarat Kidney And Superspeciality Private Limited / Previously known as Vihaan Medicare Private Limited

CIN : L85300GJ2019PLC111559

Reg. Office : Plot No.1, City Survey No 1537/A, Gokak Mill Compound, Jetalpur Road, Alkapuri,

Vadodara - 390020, Gujarat, India. E-mail : info@gujaratsuperspecialityhospital.com / www.gujaratsuperspecialityhospital.com

For Appointment Please Dial ☎ 0265 - 2984 800 / +91 96870 79991

- 5) Appointment of Additional Director: The Board has appointed Mr. (Dr) Paresh Dhoti (DIN: 11802188) as Additional- Non Executive- Independent Director with effect from 14.08.2026


The details as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 and SEBI Circular No. SEBI/HO/CFD/CFDPoD-2/CIR/P/2024/185 dated December 31, 2024 is enclosed as **Annexure A**

The Meeting commenced at 4:00 P.M. and concluded at 5 P.M.

You are requested to kindly take the same on record.

Thanking You.

For Gujarat Kidney and Super Speciality Limited


Pragnesh Bharpoda

Managing Director

DIN: 01033141

GUJARAT KIDNEY AND SUPERSPECIALITY LIMITED

CIN: L85300GJ2019PLC111559

Standalone Financial Result for the period ended on 30 June 2026

Rs. in Lacs

Sr No	Particulars	Quarter Ended		Year Ended	
		30 June 2026	31 March 2026	30 June 2025	31 March 2026
		Un Audited	Un Audited	Un Audited	Audited
I	Income				
	Revenue From Operations	924.27	924.32	1,144.99	4,010.02
	Other Income	64.52	45.06	0.15	49.45
	Total Income (I)	988.79	969.38	1,145.14	4,059.47
II	Expenses				
	Cost of materials consumed	142.64	120.75	124.61	472.27
	Employee benefits expense	149.71	144.49	136.95	558.43
	Finance costs	35.17	49.69	12.69	114.93
	Depreciation and amortization expense	63.73	67.18	79.78	294.18
	Other expenses	332.32	501.55	250.86	1,364.96
	Total expenses (II)	723.57	883.66	604.89	2,804.77
III	Profit/(loss) before tax (I-II)	265.22	85.72	540.25	1,254.70
IV	Tax expenses				
	Current tax	63.30	(9.97)	155.37	317.30
	Deferred tax	(1.79)	(41.34)	(5.10)	(52.99)
	Prior period tax	-	0.25	-	0.25
	Total Tax expense (IV)	61.51	(51.06)	150.27	264.56
V	Profit/(loss) after tax for the period (III-IV)	203.71	136.78	389.98	990.14
VI	Other Comprehensive Income				
	OCI that will not be reclassified to P&L	(0.39)	5.32	1.45	12.19
	OCI Income tax of items that will not be reclassified to P&L	0.10	(1.34)	(0.36)	(3.07)
	Total Other Comprehensive Income (VI)	(0.29)	3.98	1.09	9.12
VII	Total Comprehensive Income for the period (V+VI)	203.42	140.76	391.07	999.26
VIII	Earnings per equity share				
	Basic	0.26	0.22	0.69	1.59
	Diluted	0.26	0.22	0.69	1.59

For and on behalf of Board of Directors

GUJARAT KIDNEY AND SUPERSPECIALITY LIMITED


Dr Pragmesh Y Bhargava

Managing Director

DIN: 01033141


Place: Vadodara

Date: 14/08/2026

GUJARAT KIDNEY AND SUPERSPECIALITY LIMITED
Notes to the Standalone Financial Result for the period ended on 30 June 2026

- 1 The Above Standalone Quarterly Unaudited Financial Results of M/s. Gujarat Kidney & Superspeciality Limited for the quarter have been reviewed and recommended by the Audit Committee and the same has been approved by the Board of Directors of the Company at its meeting held on 14.08.2026. This Results have been subjected to limited Review by the statutory Auditor of the company M/s Y M Shah & Co. who have issued unmodified limited review report.
- 2 These standalone financial results have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) 34 - Interim Financial Reporting, as prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder, and in compliance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and other accounting principles generally accepted in India
- 3 As the Company's business activity falls within a single primary business segment, the disclosure requirements as per Ind-AS 108 "operating segments" are not applicable.
- 4 The Earning Per Shares has been computed in accordance with Indian Accounting Standard on Earning Per Shares (IND AS 33).
- 5 This statement is prepared as per Indian Accounting Standards (IND AS) notified under section 133 under Companies Act, 2013 read with Companies Act 2015 (Indian Accounting Standard Rules) as ammended and as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.
- 6 Previous period's / year figures have been regrouped / rearranged wherever consider necessary to confirm to the current period's / year classification.

For and on behalf of Board of Directors,
GUJARAT KIDNEY AND SUPERSPECIALITY LIMITED



Dr Pragnesh T Bharpoda .
Managing Director
DIN: 01033141

Place: Vadodara
Date: 14/08/2026

Independent Auditor's Review Report on the Quarter Ended Un-Audited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Review Report to The Board of Directors

Gujarat Kidney And Superspeciality Limited.


1. We have reviewed the accompanying statement of unaudited standalone financial results of Gujarat Kidney and Superspeciality Limited (the "Company") for the 1st quarter Ended 30th June 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/CMD1/44/2019, dated 29-03-2019. (The Circular).
2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (IND AS 34) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2013 read with SEBI Circular No. CIR/CFD/CMD1/44/2019, is the responsibility of the Company's management and has been taken on record by the Board of Directors of the Company. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2014, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards (IND AS) specified under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed or that it contains any material misstatement.
5. The accompanying IND AS financial results for the corresponding quarter ended 30-06-2026, have been subject to a limited review or audit and based on the information compiled by Management and has been taken on record by the Board of Directors.

Date: 14.08.2026

Place: Vadodara



FOR Y. M. SHAH & Co.
Chartered Accountants
F. R. No.: 114124W



Yogesh Shah
Partner

M. No. 044305

UDIN: 26044305QBKCV08858


GUJARAT KIDNEY AND SUPERSPECIALITY LIMITED

CIN: L85300GJ2019PLC111559

Consolidated Financial Result for the period ended on 30 June 2026

Rs. in Lacs

Sr No	Particulars	Quarter Ended			Year Ended
		30 June 2026	31 March 2026	30 June 2025	31 March 2026
		Un Audited	Un Audited	Un Audited	Audited
I	Income				
	Revenue From Operations	3,428.92	3,057.85	1,526.02	8,201.34
	Other Income	68.90	71.32	0.83	87.26
	Total Income (I)	3,497.82	3,129.17	1,526.85	8,288.60
II	Expenses				
	Cost of materials consumed	434.12	336.96	139.11	911.50
	Employee benefits expense	528.56	534.69	208.23	1,364.00
	Finance costs	66.45	81.80	18.07	187.82
	Depreciation and amortization expense	143.77	150.61	96.41	469.96
	Other expenses	1,628.57	1,556.53	316.12	3,231.85
	Total expenses (II)	2,801.47	2,660.59	777.94	6,165.13
III	Profit/(loss) before tax (I-II)	696.35	468.58	748.91	2,123.47
IV	Tax expenses				
	Current tax	178.75	51.20	214.10	521.03
	Deferred tax	(14.50)	(63.11)	(5.51)	(76.63)
	Prior period tax	-	(2.11)	-	(2.11)
	Total Tax expense (IV)	164.25	(14.03)	208.59	442.28
V	Profit/(loss) after tax for the period (III-IV)	532.10	482.60	540.32	1,681.18
VI	Other Comprehensive Income				
	OCI that will not be reclassified to P&L	26.39	(3.49)	0.74	5.64
	OCI Income tax of items that will not be reclassified to P&L	(6.38)	(6.18)	(0.19)	(8.61)
	Total Other Comprehensive Income (VI)	20.01	(9.66)	0.55	(2.96)
VII	Total Comprehensive Income for the period (V+VI)	552.11	472.94	540.87	1,678.22
VIII	Profit/(loss) after tax for the period (III-IV) attributable to:				
	-Owners of the company	518.15	504.19	484.48	1,549.69
	-Non-Controlling Interests	13.96	(21.59)	55.85	131.49
		532.11	482.60	540.33	1,681.18
IX	Total Other Comprehensive Income (VI) attributable to:				
	-Owners of the company	21.56	(12.85)	0.84	(6.00)
	-Non-Controlling Interests	(1.55)	3.18	(0.29)	3.04
		20.01	(9.66)	0.55	(2.96)
X	Total Comprehensive Income for the period (V+VI) attributable to:				
	-Owners of the company	539.71	491.34	485.32	1,543.68
	-Non-Controlling Interests	12.41	(18.41)	55.55	134.54
		552.12	472.94	540.87	1,678.22
XI	Earnings per equity share				
	Basic	0.66	0.81	0.85	2.49
	Diluted	0.66	0.81	0.85	2.49

For and on behalf of Board of Directors,
GUJARAT KIDNEY AND SUPERSPECIALITY LIMITED



Dr Pragnesh Y Bharpoda
Managing Director
DIN: 01033141

Place: Vadodara
Date: 14/08/2026

GUJARAT KIDNEY AND SUPERSPECIALITY LIMITED
Notes to the Consolidated Financial Result for the period ended on 30 June 2026

- 1 The Above Consolidated Quarterly Unaudited Financial Results of M/s. Gujarat Kidney & Superspeciality Limited for the quarter have been reviewed and recommended by the Audit Committee and the same has been approved by the Board of Directors of the Company at its meeting held on 14.08.2026. This Results have been subjected to limited Review by the statutory Auditor of the company M/s Y M Shah & Co. who have issued unmodified limited review report.
- 2 These Consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) 34 - Interim Financial Reporting, as prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder, and in compliance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and other accounting principles generally accepted in India
- 3 As the Company's business activity falls within a single primary business segment, the disclosure requirements as per Ind-AS 108 "operating segments" are not applicable.
- 4 The Earning Per Shares has been computed in accordance with Indian Accounting Standard on Earning Per Shares (IND AS 33).
- 5 This statement is prepared as per Indian Accounting Standards (IND AS) notified under section 133 under Companies Act, 2013 read with Companies Act 2015 (Indian Accounting Standard Rules) as ammended and as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.
- 6 Previous period's / year figures have been regrouped / rearranged wherever consider necessary to confirm to the current period's / year classification.

For and on behalf of Board of Directors,
GUJARAT KIDNEY AND SUPERSPECIALITY LIMITED


Dr Pragfesh Y Bharpoda
Managing Director
DIN: 01033141

Place: Vadodara
Date: 14/08/2026

Independent Auditor's Review Report on the Quarter Ended Un-Audited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.


Review Report to The Board of Directors

Gujarat Kidney And Superspeciality Limited.

1. We have reviewed the accompanying statement of unaudited Consolidated financial results of Gujarat Kidney and Superspeciality Limited (the "Company") for the 1st quarter Ended 30th June 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/CMD1/44/2019, dated 29-03-2019. (The Circular).
2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (IND AS 34) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2013 read with SEBI Circular No. CIR/CFD/CMD1/44/2019, is the responsibility of the Company's management and has been taken on record by the Board of Directors of the Company. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2014, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards (IND AS) specified under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed or that it contains any material misstatement.
5. The accompanying IND AS Consolidated financial results for the corresponding quarter ended 30-06-2026, have been subject to a limited review or audit and based on the information compiled by Management and has been taken on record by the Board of Directors.

Date: 14.08.2026

Place: Vadodara

FOR Y. M. SHAH & Co.
Chartered Accountants
F. R. No.: 114124WYogesh Shah
Partner
M. No. 044305
UDIN: 26044305AKLJHS4787



Date: 14.08.2026

To,
BSE Limited
Listing Department
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai - 400 001

To,
National Stock Exchange of India Limited
Listing Department "Exchange Plaza,"
C-1, Block G, Bandra - Kurla Complex,
Bandra (E), Mumbai - 400 051

Scrip Code: 544666

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Appointment of Additional Non-Executive Independent Director

Dear Sir

Pursuant to Regulation 30 of the Listing Regulations, it is hereby informed that based on the recommendation of the Nomination and Remuneration Committee of the Board, the Board of Directors of the Company in its Meeting today, 14-08-2026, has appointed Mr. Paresh Dhote (DIN: 11802188) as an Additional Non-Executive Independent Director, not liable to retire by rotation, for a first term of five consecutive years, subject to the approval by the Members of the Company.

The Board had appointed him as Non Executive Non Independent Director in its meeting held on 09.07.2026. Today his category is changed to Non Executive Independent Director with effect from 14.08.2026.

The appointment shall be subject to the approval of Members at the ensuing Annual General Meeting of the Company and compliance with Regulation 17(1C) and Regulation 25(2A) of the Listing Regulations and the relevant provisions of the Companies Act, 2013 shall be followed.

Details with respect to the said appointment as required under Regulation 30(6) read with Para A (7) of Part - A of Schedule III of the SEBI Listing Regulations and SEBI Circular No. SEBI/HO/CFD/CFD PoD1/P/CIR/2023/123 dated 13th July 2023 are provided in Annexure A to this letter.

Kindly take the same on your records.

Thanking you,

For Gujarat Kidney And Super Speciality Limited


Pragnesh Bhargava
Managing Director
DIN: 01033141

Gujarat Kidney And Superspeciality Limited

Formerly known as Gujarat Kidney And Superspeciality Private Limited / Previously known as Vihaan Medicare Private Limited
CIN : L85300GJ2019PLC111559

Reg. Office : Plot No.1, City Survey No 1537/A, Gokak Mill Compound, Jetalpur Road, Alkapuri,
Vadodara - 390020, Gujarat, India. E-mail : info@gujaratsuperspecialityhospital.com / www.gujaratsuperspecialityhospital.com

For Appointment Please Dial ☎ 0265 - 2984 800 / +91 96870 79991

ANNEXURE A


Details with respect to appointment of Additional Non-Executive Independent Director under Regulation 30(6) read with Para A (7) of Part A of Schedule III of the Listing Regulations and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July 2023:

Appointment of Mr. Paresh Dhoti as the Additional Non-Executive Independent Director

S. No.	Particulars	Description
1	Reason for change viz. appointment, resignation, removal, death or otherwise	Mr Paresh Dhoti was appointed as Non Executive Non Independent Director in the Board meeting held on 09.07.2026. He is now been appointed as an Additional Non-Executive Independent Director, not liable to retire by rotation, for a first term of five consecutive years, subject to the approval by the Members of the Company.
2	Date of appointment/ resignation & term of appointment.	14.08.2026
3	Brief profile (in case of appointment)	Mr Paresh Dhoti obtained Bachelor of Dentistry in the year 2006 from Government Medical College, Ahmedabad. Thereafter he started practicing as a Dentist and for last 18 years he is practicing independently in Vadodara.
4	Disclosure of relationships between directors (in case of appointment of a director).	Mr Paresh Dhoti is not related to any Director of the Company

This is for your information and records.

For Gujarat Kidney and Super Speciality Limited


Pragnesh Bhargava
Managing Director
DIN: 01033141